Stimulation of ovulation with human chorionic gonadotropin may cause superovulation and the hyperstimulation syndrome. Estrogen assays help detect this excessive response so that human chorionic gonadotropin may be withheld in that particular treatment cycle.
Human chorionic gonadotropin may induce sexual precocity in males treated for cryptorchidism, necessitating a reduced dosage regimen in such cases.
Further, in males, high dosages of human chorionic gonadotropin may result in edema and in such instances dosages should be considerably reduced.
The product should be used cautiously in patients with cardiac problems that may be aggravated by fluid retention, patients with asthma, renal disorder, seizure, or migraine.
Human chorionic gonadotropin should be used with extreme caution in patients with active thrombophlebitis or other active thromboembolic disorders. Caution is also warranted in patients having risk factors of thromboembolic events such as those with prior medical or family history.